Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.


Updates from The Motley Fool

Latest updates on Cardiome Pharma from Fool.com.
3 Top Stocks at Half-Price

Investors still think highly of these companies, despite their fire-sale prices.

The FDA Stands Up Cardiome

What does the approvable letter mean for Cardiome and other drug developers?



Stock Performance

View Interactive CRME Charts
Sponsored by

Key Data Points

Primary metrics and data points about Cardiome Pharma.
Current Price: $4.13
Prev Close: $4.14
Open: $4.03
Bid: $4.13
Ask: $4.15
Day's Range: $4.02 - $4.15
52wk Range: $2.35 - $5.75
Volume: 8,128
Avg Vol 113,365
Market Cap: $132M
P/E (ttm): -46.00
EPS (ttm): ($0.09)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Cardiome Pharma.
CAPS Rating 1 out of 5
 
178 Outperform
27 Underperform
CAPS All Stars
 
30 Outperform
15 Underperform

How do you think Cardiome Pharma will perform against the market?



You pick for Cardiome Pharma is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

William Hunter, M.D., CEO

34% Approve

Based on 6 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Cardiome Pharma.

Life sciences company focused on developing proprietary drugs to treat or prevent cardiovascular diseases. Current efforts are focused on the treatment of atrial arrhythmias and congestive heart failure.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers